SRC and thyroid cancer: The combined inhibition of Src and the MAPK pathway holds great promise for improving the overall survival of advanced thyroid cancer patients with Braf and Ras mutations, and activation of the PI3K pathway represents an important biomarker of response for patients treated with this therapy [78].